Adagrasib (Krazati) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Adagrasib (Krazati – Mirati Therapeutics), a RAS GTPase family inhibitor, has received accelerated approval from the FDA for oral treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy. Accelerated approval was based on the objective response rate and duration of response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Adagrasib (Krazati) for NSCLC (online only). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668f
Vancouver
Adagrasib (Krazati) for NSCLC (online only). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668f
BibTeX
@article{euvimed2023,
title = {Adagrasib (Krazati) for NSCLC (online only)},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668f}
}
EUVIMED